AVID BIOSERVICES INC (CDMO)
US05368M1062 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to CDMO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.5. This target is 91.64% above the current price.
CDMO was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about CDMO.
In the previous month the buy percentage consensus was at a similar level.
CDMO was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-11 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2024-03-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-12-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-12-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-12-08 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-09-28 | William Blair | Initiate | Market Perform |
| 2023-09-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-06-22 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-06-22 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-03-14 | Keybanc | Upgrade | Sector Weight -> Overweight |
| 2023-03-14 | RBC Capital | Reiterate | Outperform |
| 2023-03-14 | Stephens & Co. | Reiterate | Overweight |
| 2022-12-07 | RBC Capital | Maintains | Outperform |
| 2022-06-30 | RBC Capital | Maintains | Outperform |
| 2022-03-09 | Stephens & Co. | Maintains | Overweight |
| 2021-12-08 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2021-12-08 | RBC Capital | Maintains | Outperform |
| 2021-12-08 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Keybanc | Maintains | Overweight |
| 2021-06-30 | RBC Capital | Maintains | Outperform |
| 2021-06-30 | Craig-Hallum | Maintains | Buy |
| 2021-03-17 | RBC Capital | Initiate | Outperform |